FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385383500> ?p ?o ?g. }

• W4385383500 abstract "RG6346 is an N-acetyl-D-galactosamine (GalNAc)-conjugated, double-stranded RNA interference agent targeting the HBV genome S-region. We investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of RG6346 in healthy volunteers and patients with chronic HBV infection (CHB).This first-in-human, adaptive, randomized, double-blinded, phase I study recruited three groups of participants: Group A, 30 healthy volunteers received single-dose RG6346 at 0.1, 1.5, 3.0, 6.0, or 12.0 mg/kg, or placebo; Group B, nucleos(t)ide analogue-naïve participants with CHB received single-dose RG6346 at 3.0 mg/kg (n = 6) or placebo (n = 3); Group C, participants with nucleos(t)ide-suppressed CHB received four doses (every 28 days) of RG6346 at 1.5, 3.0, or 6.0 mg/kg (n = 4 in each cohort) or placebo (n = 6).RG6346 treatment for up to 4 months was safe and well tolerated. The most common adverse event was a mild injection site reaction. Several nucleos(t)ide-naïve participants exhibited self-resolving transaminase elevations with preserved liver function. By the end of RG6346 treatment in Group C (Day 112), the mean reduction from baseline in hepatitis B surface antigen (HBsAg) was 1.39, 1.80, and 1.64 log10 IU/ml in the 1.5, 3.0, and 6.0 mg/kg cohorts, respectively. Of the 12 participants in Group C, 11 (91.7%) achieved a ≥1 log10 IU/ml reduction in HBsAg (3 of 11 [27.3%] had the response sustained at conditional follow-up Day 448). No dose-response relationship was apparent between RG6346 and serum HBsAg levels. The RG6346-induced HBsAg response was independent of hepatitis B e antigen status. Moderate-to-marked sustained reductions of hepatitis B core-related antigen, HBV RNA, HBV DNA (in nucleos[t]ide analogue-naïve participants), and hepatitis B e antigen levels were observed.These favorable safety and pharmacodynamic data support the clinical development of RG6346 as the backbone of a finite antiviral treatment regimen, with the goal of sustained HBsAg loss (functional cure) in patients with CHB.ClinicalTrials.gov NCT03772249.Currently available therapies for chronic HBV infection are associated with low rates of functional cure and new, more efficacious treatments are needed. This first-in-human study of RG6346, an RNA interference therapy, showed a favorable safety profile as well as marked and durable reductions in hepatitis B surface antigen levels. These results support the continued development of RG6346 as the backbone of a finite treatment regimen targeting high functional cure rates and are important for HBV researchers and physicians." @default.
• W4385383500 created "2023-07-30" @default.
• W4385383500 creator A5016169761 @default.
• W4385383500 creator A5019669804 @default.
• W4385383500 creator A5031583663 @default.
• W4385383500 creator A5035961207 @default.
• W4385383500 creator A5044560216 @default.
• W4385383500 creator A5062263962 @default.
• W4385383500 creator A5066110089 @default.
• W4385383500 creator A5066288177 @default.
• W4385383500 creator A5073784411 @default.
• W4385383500 creator A5074915165 @default.
• W4385383500 creator A5077160653 @default.
• W4385383500 creator A5083960272 @default.
• W4385383500 creator A5089108312 @default.
• W4385383500 creator A5089269281 @default.
• W4385383500 date "2023-07-01" @default.
• W4385383500 modified "2023-10-18" @default.
• W4385383500 title "First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection" @default.
• W4385383500 cites W1906881483 @default.
• W4385383500 cites W1996594959 @default.
• W4385383500 cites W2002144368 @default.
• W4385383500 cites W2040760136 @default.
• W4385383500 cites W2072967413 @default.
• W4385383500 cites W2114785561 @default.
• W4385383500 cites W2164901745 @default.
• W4385383500 cites W2531694387 @default.
• W4385383500 cites W2605785536 @default.
• W4385383500 cites W2633859106 @default.
• W4385383500 cites W2739640246 @default.
• W4385383500 cites W2786264829 @default.
• W4385383500 cites W2791839818 @default.
• W4385383500 cites W2801666689 @default.
• W4385383500 cites W2803566305 @default.
• W4385383500 cites W2984221112 @default.
• W4385383500 cites W2995694266 @default.
• W4385383500 cites W3005196371 @default.
• W4385383500 cites W3031206422 @default.
• W4385383500 cites W3036498507 @default.
• W4385383500 cites W3063613132 @default.
• W4385383500 cites W3107667683 @default.
• W4385383500 cites W3125147233 @default.
• W4385383500 cites W3145607668 @default.
• W4385383500 cites W3164796831 @default.
• W4385383500 cites W3165162313 @default.
• W4385383500 cites W3188329189 @default.
• W4385383500 cites W3198634082 @default.
• W4385383500 cites W3211797588 @default.
• W4385383500 cites W4205354877 @default.
• W4385383500 doi "https://doi.org/10.1016/j.jhep.2023.07.026" @default.
• W4385383500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37524230" @default.
• W4385383500 hasPublicationYear "2023" @default.
• W4385383500 type Work @default.
• W4385383500 citedByCount "0" @default.
• W4385383500 crossrefType "journal-article" @default.
• W4385383500 hasAuthorship W4385383500A5016169761 @default.
• W4385383500 hasAuthorship W4385383500A5019669804 @default.
• W4385383500 hasAuthorship W4385383500A5031583663 @default.
• W4385383500 hasAuthorship W4385383500A5035961207 @default.
• W4385383500 hasAuthorship W4385383500A5044560216 @default.
• W4385383500 hasAuthorship W4385383500A5062263962 @default.
• W4385383500 hasAuthorship W4385383500A5066110089 @default.
• W4385383500 hasAuthorship W4385383500A5066288177 @default.
• W4385383500 hasAuthorship W4385383500A5073784411 @default.
• W4385383500 hasAuthorship W4385383500A5074915165 @default.
• W4385383500 hasAuthorship W4385383500A5077160653 @default.
• W4385383500 hasAuthorship W4385383500A5083960272 @default.
• W4385383500 hasAuthorship W4385383500A5089108312 @default.
• W4385383500 hasAuthorship W4385383500A5089269281 @default.
• W4385383500 hasConcept C111113717 @default.
• W4385383500 hasConcept C112705442 @default.
• W4385383500 hasConcept C126322002 @default.
• W4385383500 hasConcept C142724271 @default.
• W4385383500 hasConcept C181199279 @default.
• W4385383500 hasConcept C197934379 @default.
• W4385383500 hasConcept C203014093 @default.
• W4385383500 hasConcept C204787440 @default.
• W4385383500 hasConcept C2522874641 @default.
• W4385383500 hasConcept C27081682 @default.
• W4385383500 hasConcept C2776877979 @default.
• W4385383500 hasConcept C2777382497 @default.
• W4385383500 hasConcept C2777410769 @default.
• W4385383500 hasConcept C2778375690 @default.
• W4385383500 hasConcept C2780593183 @default.
• W4385383500 hasConcept C55493867 @default.
• W4385383500 hasConcept C71924100 @default.
• W4385383500 hasConcept C72563966 @default.
• W4385383500 hasConcept C86803240 @default.
• W4385383500 hasConcept C90924648 @default.
• W4385383500 hasConceptScore W4385383500C111113717 @default.
• W4385383500 hasConceptScore W4385383500C112705442 @default.
• W4385383500 hasConceptScore W4385383500C126322002 @default.
• W4385383500 hasConceptScore W4385383500C142724271 @default.
• W4385383500 hasConceptScore W4385383500C181199279 @default.
• W4385383500 hasConceptScore W4385383500C197934379 @default.
• W4385383500 hasConceptScore W4385383500C203014093 @default.
• W4385383500 hasConceptScore W4385383500C204787440 @default.
• W4385383500 hasConceptScore W4385383500C2522874641 @default.
• W4385383500 hasConceptScore W4385383500C27081682 @default.
• W4385383500 hasConceptScore W4385383500C2776877979 @default.

• next